JPMorgan analyst Andrea Teixeira lowered the firm’s price target on Clorox (CLX) to $144 from $151 and keeps a Neutral rating on the shares. The firm updated the company’s model post the fiscal Q3 report. Clorox missed organic sales growth and adjusted earnings expectations, and management lowered high end of fiscal 2025 sales guidance due to a slowdown in consumption and retailer destocking, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLX:
- Clorox’s Financial Outlook: Hold Rating Amid Sales Guidance Revision and Market Challenges
- Clorox price target lowered to $142 from $145 at Wells Fargo
- Clorox Reports Q3 2025 Results Amid Sales Decline
- Closing Bell Movers: Palantir falls 9%, Ford down 2% on earnings
- Clorox Reports Q3 2025 Results with Sales Decline